Clinical Trial Update: Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) [Phase 2]

View source ↗

Summary

A Phase 2 trial is investigating induction therapy with gemcitabine, docetaxel, and toripalimab for EBV-associated nasopharyngeal carcinoma. The study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Stanford University | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: RECRUITING